Messenger RNA Diagnostic/Treatment Paradigm VANCOUVER, BC, Nov. 9, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has filed a genetic neuroinflammatory…

Source

Previous articlePTSF84 – A Brief Check-in From Wonderland
Next articlePsychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results